id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0389-0008,FDA,FDA-2011-E-0389,FDA\CDER to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T15:51:29Z,,0,0,090000648119c7d6
FDA-2011-E-0389-0007,FDA,FDA-2011-E-0389,Determination of Regulatory Review Periods for Patent Extension: VIIBRYD,Notice,General Notice,2012-04-06T04:00:00Z,2012,4,2012-04-06T04:00:00Z,2012-05-06T03:59:59Z,2014-08-20T13:01:36Z,2012-08341,0,0,0900006480feaa04
FDA-2011-E-0389-0006,FDA,FDA-2011-E-0389,FDA\CDER to United States Patent and Trademark Office - Letter,Other,Letter(s),2012-04-03T04:00:00Z,2012,4,2012-04-03T04:00:00Z,,2012-04-03T19:08:10Z,,0,0,0900006480fe7bb3
FDA-2011-E-0389-0005,FDA,FDA-2011-E-0389,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-03-12T04:00:00Z,2012,3,2012-03-12T04:00:00Z,,2012-03-12T15:21:46Z,,0,0,0900006480fd3b8b